A baby girl with Alagille syndrome and related liver problems that were not responding to standard medication was also…
Articles by Margarida Maia, PhD
Lynavoy (linerixibat) is now approved in the U.S. as an oral treatment for cholestatic pruritus, or intense itch due to…
Progressive familial intrahepatic cholestasis type 3 (PFIC3) can cause abnormalities in copper metabolism that mimic another condition, Wilson’s disease,…
Volixibat, Mirum Pharmaceuticals’ experimental oral treatment, may help reduce circulating bile acids and ease itch in pregnant women with…
A committee of the European Medicines Agency (EMA) has recommended that Kayshild (semaglutide), marketed in the U.S. and Canada as…
International Alagille Syndrome Awareness Day is tomorrow, Jan. 24, and the advocacy organization Alagille Syndrome Alliance is calling on…
Liver transplant may help prevent bile duct cancer in people with primary sclerosing cholangitis (PSC) who have advanced…
Livmarli (maralixibat) and Bylvay (odevixibat) not only offer significant relief from severe itching in children with Alagille…
The experimental oral therapy linerixibat from GlaxoSmithKline (GSK) offers rapid and sustained relief from severe itch in adults with…
Two new mutations in the USP53 gene were identified as the cause of a milder form of progressive familial…